Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justin F Gainor

Showing results (11-20 of 219) with videos related to

Pageof 22
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2018
ARCHER 1050: Hitting an Important Mark in EGFR-Mutant Lung Cancer?Zofia Piotrowska, Justin F Gainor
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2022
Selective Targeting of RET Fusions in Lung CancerJessica J Lin, Justin F Gainor
Translational Lung Cancer Research|February 26, 2024
Current opportunities and challenges in ALK-positive lung cancerJessica J Lin, Justin F Gainor
The Oncologist|July 2, 2013
Novel targets in non-small cell lung cancer: ROS1 and RET fusionsJustin F Gainor, Alice T Shaw
The Lancet. Oncology|March 17, 2018
ATLANTIC: a sea change in immunotherapy for oncogene-driven lung cancer?Jessica J Lin, Justin F Gainor
JAMA Oncology|November 22, 2023
Osimertinib in Patients With Non-Small Cell Lung Cancer and Uncommon EGFR Mutations-Chasing Unicorns?Victoria E Wang, Justin F Gainor
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2022
Human Epidermal Growth Factor Receptor 2-Mutant Non-Small-Cell Lung Cancer: Continued Progress But Challenges RemainAlissa J Cooper, Justin F Gainor
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2026
Recalibrating Dual Checkpoint Blockade? Lessons from VolrustomigJong Chul Park, Justin F Gainor
British Journal of Cancer|March 24, 2021
An early look at selective RET inhibitor resistance: new challenges and opportunitiesJessica J Lin, Justin F Gainor
The Lancet. Respiratory Medicine|December 19, 2022
First-line lorlatinib for advanced ALK-positive non-small-cell lung cancerJessica J Lin, Justin F Gainor
Pageof 22

Showing results (11-20 of 219) with videos related to

Sort By:
Pageof 22
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2018
ARCHER 1050: Hitting an Important Mark in EGFR-Mutant Lung Cancer?Zofia Piotrowska, Justin F Gainor
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 19, 2022
Selective Targeting of RET Fusions in Lung CancerJessica J Lin, Justin F Gainor
Translational Lung Cancer Research|February 26, 2024
Current opportunities and challenges in ALK-positive lung cancerJessica J Lin, Justin F Gainor
The Oncologist|July 2, 2013
Novel targets in non-small cell lung cancer: ROS1 and RET fusionsJustin F Gainor, Alice T Shaw
The Lancet. Oncology|March 17, 2018
ATLANTIC: a sea change in immunotherapy for oncogene-driven lung cancer?Jessica J Lin, Justin F Gainor
JAMA Oncology|November 22, 2023
Osimertinib in Patients With Non-Small Cell Lung Cancer and Uncommon EGFR Mutations-Chasing Unicorns?Victoria E Wang, Justin F Gainor
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 24, 2022
Human Epidermal Growth Factor Receptor 2-Mutant Non-Small-Cell Lung Cancer: Continued Progress But Challenges RemainAlissa J Cooper, Justin F Gainor
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2026
Recalibrating Dual Checkpoint Blockade? Lessons from VolrustomigJong Chul Park, Justin F Gainor
British Journal of Cancer|March 24, 2021
An early look at selective RET inhibitor resistance: new challenges and opportunitiesJessica J Lin, Justin F Gainor
The Lancet. Respiratory Medicine|December 19, 2022
First-line lorlatinib for advanced ALK-positive non-small-cell lung cancerJessica J Lin, Justin F Gainor
Pageof 22